Therapies that target estrogen synthesis or ER function, such as aromatase inhibitors and selective estrogen receptor modulators, have been used successfully to treat patients diagnosed with ER+ breast cancer with improvements in survival (reviewed in ref. 1). Here, CYP19A1 is linked to breast cancer.